Genmab A/S (GMAB)
51.37
-0.37
(-0.72%)
USD |
NASDAQ |
Nov 13, 16:00
52.12
+0.74
(+1.45%)
After-Hours: 06:24
Genmab EPS Diluted (Quarterly) : 0.5475 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.5475 |
| June 30, 2026 | 0.4903 |
| March 31, 2026 | 0.0833 |
| December 31, 2025 | 0.0461 |
| September 30, 2025 | 0.6431 |
| June 30, 2025 | 0.5537 |
| March 31, 2025 | 0.3052 |
| December 31, 2024 | 0.8529 |
| September 30, 2024 | 0.2917 |
| June 30, 2024 | 0.3132 |
| March 31, 2024 | 0.2938 |
| December 31, 2023 | 0.1395 |
| September 30, 2023 | 0.4662 |
| June 30, 2023 | 0.2963 |
| March 31, 2023 | 0.046 |
| December 31, 2022 | 0.1209 |
| September 30, 2022 | 0.5301 |
| June 30, 2022 | 0.41 |
| March 31, 2022 | 0.1063 |
| December 31, 2021 | 0.1663 |
| September 30, 2021 | 0.2135 |
| June 30, 2021 | 0.0752 |
| March 31, 2021 | 0.269 |
| December 31, 2020 | 0.1402 |
| September 30, 2020 | 0.1262 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.7582 |
| March 31, 2020 | 0.0603 |
| December 31, 2019 | 0.336 |
| September 30, 2019 | 0.1234 |
| June 30, 2019 | 0.0203 |
| March 31, 2019 | 0.0178 |
| December 31, 2018 | 0.2055 |
| September 30, 2018 | 0.0451 |
| June 30, 2018 | 0.0673 |
| March 31, 2018 | 0.0528 |
| December 31, 2017 | 0.2001 |
| September 30, 2017 | -0.0014 |
| June 30, 2017 | 0.0733 |
| March 31, 2017 | 0.0037 |
| December 31, 2016 | 0.1973 |
| September 30, 2016 | 0.0459 |
| June 30, 2016 | 0.0413 |
| March 31, 2016 | -0.0028 |
| December 31, 2015 | 0.0946 |
| September 30, 2015 | 0.0343 |
| June 30, 2015 | 0.004 |
| March 31, 2015 | 0.0549 |
| December 31, 2014 | 0.02 |
| September 30, 2014 | 0.0494 |
| June 30, 2014 | -0.0085 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AbbVie, Inc. | 2.373 |
| Incyte Corp. | -3.861 |
| Ascendis Pharma A/S | 1.239 |
| Zealand Pharma A/S | -0.1216 |
| Bavarian Nordic A/S | 0.305 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 341.65M |
| Revenue (Quarterly) | 1.186B |
| Total Expenses (Quarterly) | 844.13M |
| Enterprise Value | 34.93B |
| Gross Profit Margin (Quarterly) | 90.31% |
| Profit Margin (Quarterly) | 28.81% |
| Earnings Yield | 2.27% |
| Operating Earnings Yield | 4.01% |
| Normalized Earnings Yield | 2.835 |